## Rodolfo Hurle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2384332/publications.pdf

Version: 2024-02-01

331259 276539 1,797 50 21 41 h-index citations g-index papers 51 51 51 2050 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Impact on Sexual Function of Holmium Laser Enucleation Versus Transurethral Resection of the Prostate: Results of a Prospective, 2-Center, Randomized Trial. Journal of Urology, 2006, 175, 1817-1821.	0.2	162
2	En bloc resection of urothelium carcinoma of the bladder (EBRUC): a European multicenter study to compare safety, efficacy, and outcome of laser and electrical en bloc transurethral resection of bladder tumor. World Journal of Urology, 2015, 33, 1937-1943.	1.2	124
3	Three-Year Outcome following Holmium Laser Enucleation of the Prostate Combined with Mechanical Morcellation in 330 Consecutive Patients. European Urology, 2008, 53, 599-606.	0.9	115
4	Current Evidence of Transurethral En-bloc Resection of Nonmuscle Invasive Bladder Cancer. European Urology Focus, 2017, 3, 567-576.	1.6	106
5	Intravesical bacille Calmette-Guérin in stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. Urology, 1999, 54, 258-263.	0.5	100
6	Olfactory System of Highly Trained Dogs Detects Prostate Cancer in Urine Samples. Journal of Urology, 2015, 193, 1382-1387.	0.2	96
7	Role of Restaging Transurethral Resection for T1 Non–muscle invasive Bladder Cancer: A Systematic Review and Meta-analysis. European Urology Focus, 2018, 4, 558-567.	1.6	84
8	Upper urinary tract tumors developing after treatment of superficial bladder cancer: 7-year follow-up of 591 consecutive patients. Urology, 1999, 53, 1144-1148.	0.5	72
9	Application and Uses of Electronic Noses for Clinical Diagnosis on Urine Samples: A Review. Sensors, 2016, 16, 1708.	2.1	63
10	"En Bloc―Resection of Nonmuscle Invasive Bladder Cancer: A Prospective Single-center Study. Urology, 2016, 90, 126-130.	0.5	62
11	Holmium laser enucleation of the prostate combined with mechanical morcellation in 155 patients with benign prostatic hyperplasia. Urology, 2002, 60, 449-453.	0.5	60
12	Active Surveillance for Low Risk Nonmuscle Invasive Bladder Cancer: A Confirmatory and Resource Consumption Study from the BIAS Project. Journal of Urology, 2018, 199, 401-406.	0.2	54
13	Lipid-loaded tumor-associated macrophages sustain tumor growth and invasiveness in prostate cancer. Journal of Experimental Medicine, 2022, 219, .	4.2	53
14	Holmium Laser Enucleation of the Prostate Combined with Mechanical Morcellation: Two Years of Experience with 196 Patients. Journal of Endourology, 2004, 18, 109-112.	1.1	50
15	Mitochondrial metabolic reprogramming controls the induction of immunogenic cell death and efficacy of chemotherapy in bladder cancer. Science Translational Medicine, 2021, 13, .	5 <b>.</b> 8	50
16	Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy. Medicine (United States), 2015, 94, e1861.	0.4	43
17	Mast Cells as a Potential Prognostic Marker in Prostate Cancer. Disease Markers, 2013, 35, 711-720.	0.6	33
18	Usefulness of pT1 substaging in papillary urothelial bladder carcinoma. Diagnostic Pathology, 2016, 11, 6.	0.9	33

#	Article	IF	CITATIONS
19	Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans: an update on the evidence. Therapeutic Advances in Urology, 2016, 8, 91-99.	0.9	27
20	Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 77.e1-77.e7.	0.8	26
21	Active surveillance for lowâ€risk nonâ€muscleâ€invasive bladder cancer: midâ€term results from the Bladder cancer Italian Active Surveillance ( <scp>BIAS</scp> ) project. BJU International, 2016, 118, 935-939.	1.3	24
22	Pelvic lymphadenectomy during radical cystectomy: A review of the literature. Surgical Oncology, 2010, 19, 208-220.	0.8	23
23	High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study. Urologia Internationalis, 2018, 101, 7-15.	0.6	22
24	Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.it. Therapeutic Advances in Urology, 2012, 4, 279-301.	0.9	21
25	Clinical performance of prostate health index in men with tPSA>10ng/ml: Results from a multicentric European study. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 415.e13-415.e19.	0.8	20
26	En bloc re-resection of high-risk NMIBC after en bloc resection: results of a multicenter observational study. World Journal of Urology, 2020, 38, 703-708.	1.2	20
27	Assessing the Feasibility and Accuracy of High-resolution Microultrasound Imaging for Bladder Cancer Detection and Staging. European Urology, 2020, 77, 727-732.	0.9	20
28	Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA-based urine test, in active surveillance (AS) patients with recurrent non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Italian Active Surveillance (BIAS) project. World Journal of Urology, 2020, 38, 2215-2220.	1.2	20
29	Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer. Translational Andrology and Urology, 2021, 10, 626-635.	0.6	20
30	Development and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy. World Journal of Urology, 2015, 33, 1419-1428.	1.2	19
31	Senescent Remodeling of the Innate and Adaptive Immune System in the Elderly Men with Prostate Cancer. Current Gerontology and Geriatrics Research, 2014, 2014, 1-11.	1.6	18
32	Preoperative prostate health index is an independent predictor of early biochemical recurrence after radical prostatectomy: Results from a prospective single-center study. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 337.e7-337.e14.	0.8	15
33	Long-term outcomes of high-grade T1 bladder cancer treated with intravesical bacillus Calmette-Guérin: experience of a single center. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2018, 70, 501-508.	3.9	14
34	Pathological Outcomes for Patients Who Failed To Remain Under Active Surveillance for Low-risk Non–muscle-invasive Bladder Cancer: Update and Results from the Bladder Cancer Italian Active Surveillance Project. European Urology Oncology, 2018, 1, 437-442.	2.6	14
35	Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette–Guerin Immunotherapy. Diagnostics, 2022, 12, 586.	1.3	14
36	A Simple Mathematical Approach to Calculate Blood Loss in Radical Prostatectomy. Urologia Internationalis, 2004, 72, 135-139.	0.6	13

#	Article	IF	CITATIONS
37	Long-term Follow-up After En Bloc Transurethral Resection of Non–muscle-invasive Bladder Cancer: Results from a Single-center Experience. European Urology Open Science, 2021, 26, 64-71.	0.2	11
38	Long-term Follow-up and Factors Associated with Active Surveillance Failure for Patients with Non–muscle-invasive Bladder Cancer: The Bladder Cancer Italian Active Surveillance (BIAS) Experience. European Urology Oncology, 2022, 5, 251-255.	2.6	11
39	Xpert Bladder Cancer Monitor May Avoid Cystoscopies in Patients Under "Active Surveillance―for Recurrent Bladder Cancer (BIAS Project): Longitudinal Cohort Study. Frontiers in Oncology, 2022, 12, 832835.	1.3	11
40	Active surveillance for non-muscle invasive bladder cancer: A systematic review and pooled-analysis. Cancer Treatment and Research Communications, 2021, 27, 100369.	0.7	9
41	Oncofid-P-B: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: Results of a prospective European Multicentre study at 15 months from treatment start. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 11.e9-11.e15.	0.8	9
42	Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi-centre collaboration. World Journal of Urology, 2022, 40, 1167-1174.	1.2	9
43	Head-to-Head Comparison between High-Resolution Microultrasound Imaging and Multiparametric MRI in Detecting and Local Staging of Bladder Cancer: The BUS-MISS Protocol. Bladder Cancer, 2022, 8, 119-127.	0.2	7
44	The role of narrow-band imaging in the management of non-muscle-invasive bladder cancer. Expert Review of Anticancer Therapy, 2012, 12, 1523-1528.	1.1	6
45	A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in men with prostate cancer. Efficacy monitored by karyometry. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 557-565.	0.8	4
46	Active surveillance for recurrent low-grade non-muscle-invasive bladder cancer: Can we take any advantage from the COVID-19 crisis?. Arab Journal of Urology Arab Association of Urology, 2020, 18, 65-66.	0.7	3
47	Safety and Feasibility of Salvage Endoscopic Combined Intrarenal Surgery in Embolized Kidney. Journal of Endourology Case Reports, 2016, 2, 127-130.	0.3	2
48	In reply to: Lawless <i>et al</i> . Stalk versus base invasion in <scp>pT</scp> 1 papillary cancers of the bladder: improved substaging system predicting the risk of progression. Histopathology, 2018, 72, 361-362.	1.6	0
49	Active Surveillance for Low-Risk Non-Muscle Invasive Bladder Cancer. , 2018, , 31-34.		0
50	Enhancing the Quality of Transurethral Resection: The Importance of aÂComplete TURB and theÂEn-Bloc Resection. , 2018, , 19-29.		0